Our Board

Our experienced board provides strong oversight and governance

Robert W. Duggan joined the Board of Directors in December 2019 and has been the Executive Chairman our Board since February 2020.  Mr. Duggan has served as our Chief Executive Officer since April 2020.

Since 2015, Mr. Duggan has also been the Founder and CEO of Duggan Investments, a venture capital and equity investment firm.  His firm’s investments primarily focus on patient-friendly breakthrough solutions to complex diseases of aging.

From 2008 to 2015, Mr. Duggan was Chairman, CEO, and the largest investor in Pharmacyclics, Inc., a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of certain cancers.  Mr. Duggan led both the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Johnson & Johnson in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015.  The acquisition of Pharmacyclics by AbbVie for approximately $21B remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.

From 1990 to 2003, Mr. Duggan was Chairman of the Board of Directors of Computer Motion, Inc., a groundbreaking robotic surgery company that helped change the way in which many surgical procedures are performed around the world with the assistance of its minimally invasive, robotics-based surgical systems. From 1997 to 2003, Mr. Duggan also served as CEO of Computer Motion.  In June 2003, Computer Motion merged with Intuitive Surgical, Inc.  From the completion of the merger in 2003 until 2011, Mr. Duggan served on the Board of Directors of Intuitive Surgical.

Mr. Duggan received a US Congressional Medal of Merit from Congressman Dr. Ron Paul in 1985.  In 2000, he was named a Knight of the Legion D’Honor by President Jacques Chirac of France.

Beyond Summit, Mr. Duggan is currently the Chairman of the Board at Pulse BioSciences, Inc., and is also a member of the University of California at Santa Barbara Foundation Board of Trustees.  Mr. Duggan has also funded two Chairs in Mathematical, Life, and Physical Sciences, as well as a Chair in Religious Studies at the University of California at Santa Barbara.

Mr. Erdtmann has over 25 years of experience in the investment banking and the financial industries. He currently is a Portfolio Manager and General Partner at Point Sur Investors, a biotech focused investment fund. He also serves as President and co-founder of Biomea Health, a precision oncology company creating new generations of molecular scaffolds of targeting genetically defined diseases. Prior to Biomea Health, Mr. Erdtmann was 8 years at Pharmacyclics, Inc. (NASDAQ: PCYC) and oversaw a broad range of departments while helping to grow the company from 47-634 employees. He began leading the Finance Department and managed all Accounting, SEC Reporting, Audits and Investor Relations. He also built up and ran IT, HR, Legal, Facilities and Events for the company. Later, as the Executive Vice President of Corporate Affairs, he assumed additional responsibilities for Corporate Communications. Mr. Erdtmann actively participated in the final execution of key corporate milestones for Pharmacyclics, among them the Collaboration Agreement with J&J in 2011 (value $1 Billion) and the merger agreement with AbbVie in 2015 (value $21 Billion). Mr. Erdtmann served on the board of PolarityTE (NASDAQ PTE), a regenerative medicine company, where he was it’s Audit Committee Chair until March 2020. Mr. Erdtmann began his career at Commerzbank in Germany, where he was an investment banker and portfolio manager for large institutional accounts. He earned the Diplom Kaufmann degree with honors in finance and banking from the Westfaelische Wilhelms Universitaet of Muenster, Germany, the equivalent to a US Master of Business Administration degree.

Ms. Mahatme has over 30 years of experience in corporate law and financing in a diverse range of companies from start-ups to Fortune 500 companies, including those in the healthcare and biotechnology sector. She is the Founder and Managing Partner of Mahatme Bitterman PLLC, where she focuses on US and international clients in the healthcare/biotechnology, technology and real estate sectors. Previously, Ms. Mahatme served as Counsel at Gibson, Dunn & Crutcher and Counsel and Associate at Pillsbury Winthrop Shaw Pittman LLP. Ms. Mahatme serves on the board of Lakota Children’s Enrichment and was a past board member of the Board of Education, Lake Placid Central School District and Greenacres Association. She received her Bachelor of Commerce (accounting, business, and economics) from Brihan Maharashtra College of Commerce, University of Poona, her Bachelor of Laws (general) from ILS Law School, University of Poona, Master of Laws (general law) from the University of Cambridge and Master of Laws (corporate law) from New York University.

Mr. Manmeet Soni has extensive experience in transitioning biotechnology companies from development stage through commercialization and globalization. He is currently the Chief Operating Officer & Chief Financial Officer and Executive Vice President of Reata Pharmaceuticals, Inc. where he is responsible for overall global functions of finance, tax, treasury, internal audit, information technology, investor relations, corporate communication, and strategy functions. He has served as the Chief Financial Officer of several publicly-listed life science companies, including Pharmacyclics, Inc., where he played a vital role in the acquisition by Abbvie, Inc. for $21 billion in 2015, Ariad Pharmaceuticals Inc., where he played a major role in the acquisition by Takeda Inc. for $5.1 billion in 2017, and Alnylam Pharmaceuticals, Inc., where he raised over $2.5 billion in cash. Mr. Soni currently serves on the board of Arena Pharmaceuticals, Inc. and Pulse Biosciences, Inc. He is a certified public accountant and chartered accountant from India and received his Bachelor of Commerce from Hansraj College, Delhi University (India).

Dr. Maky Zanganeh has served as Summit’s Chief Operating Officer and has been a member of the Board of Directors since November 2020.

She has more than 15 years of management, corporate, clinical, and business experience in the pharmaceutical, medical device, and technology industries.

Most recently, Dr. Zanganeh is the Founder & CEO of Maky Zanganeh and Associates (“MZA”), which provides consulting services to businesses in product development, research, and transactions.

Prior to starting and leading MZA, Dr. Zanganeh held multiple leadership positions at Pharmacyclics, Inc., from 2008 to 2015, culminating in her role as Chief Operating Officer, where she oversaw all clinical, research, commercial, and business-related matters. Dr. Zanganeh played a key role both in the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Janssen Biotech, Inc. in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015.  The acquisition of Pharmacyclics by AbbVie remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.

Previously, she held senior positions of increasing responsibility within companies such as Robert Duggan & Associates, a private investment firm, and Computer Motion, Inc., a pioneer in robotic surgery.

Dr. Zanganeh earned FierceBiotech’s “Top Women in Biotech” award in 2013.  She received her DDS from Louis Pasteur University (France) and her MBA from Schiller International University (France).

Beyond Summit, Dr. Zanganeh is currently a board member for Pulse BioSciences, Inc. and RenovoRx, Inc.